Shoko Tsuchimine Selected Research

Paroxetine (Paxil)

1/2018	Effects of personality on the association between paroxetine plasma concentration and response.
5/2016	Items of the Montgomery-Åsberg Depression Rating Scale Associated With Response to Paroxetine Treatment in Patients With Major Depressive Disorder.
1/2016	Influence of the cytochrome P450 2D6 10/10 genotype on the pharmacokinetics of paroxetine in Japanese patients with major depressive disorder: a population pharmacokinetic analysis.
1/2015	Effects of age on paroxetine efficacy in patients with major depressive disorder who do not exhibit an early response to treatment.
8/2014	Therapeutic reference range for plasma concentrations of paroxetine in patients with major depressive disorders.
1/2014	The influence of 5-HTTLPR genotype on the association between the plasma concentration and therapeutic effect of paroxetine in patients with major depressive disorder.
1/2014	Factors affecting discontinuation of initial treatment with paroxetine in panic disorder and major depressive disorder.
1/2014	Possible impact of the CYP2D6*10 polymorphism on the nonlinear pharmacokinetic parameter estimates of paroxetine in Japanese patients with major depressive disorders.
1/2014	Sex differences in the prediction of the effectiveness of paroxetine for patients with major depressive disorder identified using a receiver operating characteristic curve analysis for early response.
10/2012	DRD3, but not BDNF, genotype affects treatment response to paroxetine in major depressive disorder: a preliminary study.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Shoko Tsuchimine Research Topics

Disease

13	Major Depressive Disorder (Major Depressive Disorders) 01/2019 - 04/2011
10	Schizophrenia (Dementia Praecox) 01/2019 - 04/2010
4	Hyperprolactinemia 03/2011 - 08/2008
3	Body Weight (Weight, Body) 10/2021 - 01/2016
2	Mental Disorders (Mental Disorder) 01/2019 - 01/2014
2	Overweight 01/2016 - 01/2013
1	Inflammation (Inflammations) 01/2021
1	Anhedonia 02/2020
1	Bipolar Disorder (Manic Depressive Psychosis) 01/2019
1	Depressive Disorder (Melancholia) 10/2018
1	Panic Disorder (Panic Attack) 01/2014
1	Alzheimer Disease (Alzheimer's Disease) 01/2014
1	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2013
1	Menorrhagia 01/2012
1	Gynecomastia 01/2012
1	Ejaculatory Dysfunction 01/2012
1	Metabolic Bone Diseases (Osteopenia) 12/2011
1	Neurobehavioral Manifestations 10/2011

Drug/Important Bio-Agent (IBA)

11	Paroxetine (Paxil)FDA LinkGeneric 01/2018 - 04/2011
5	Antipsychotic Agents (Antipsychotics)IBA 01/2012 - 08/2008
4	ProlactinIBA 12/2011 - 08/2008
3	Cytochrome P-450 CYP2D6 (CYP2D6)IBA 10/2021 - 01/2014
3	Pharmaceutical PreparationsIBA 08/2014 - 04/2010
3	Therapeutic UsesIBA 08/2014 - 10/2011
3	Risperidone (Risperdal Consta)FDA LinkGeneric 10/2011 - 04/2010
2	Biomarkers (Surrogate Marker)IBA 10/2018 - 01/2014
2	Glutathione Transferase (Glutathione S-Transferase)IBA 01/2016 - 01/2013
2	Nerve Growth Factors (Neurotrophins)IBA 01/2014 - 04/2011
2	Serotonin Plasma Membrane Transport Proteins (Serotonin Transporter)IBA 01/2014 - 01/2014
2	Brain-Derived Neurotrophic Factor (BDNF)IBA 01/2014 - 10/2012
2	Dopamine (Intropin)FDA LinkGeneric 04/2010 - 08/2008
1	ADP Ribose Transferases (ADP Ribosyltransferase)IBA 01/2021
1	SirtuinsIBA 01/2021
1	Adenosine Diphosphate (ADP)IBA 01/2021
1	Fatty Acids (Saturated Fatty Acids)IBA 01/2021
1	NAD (NADH)IBA 01/2021
1	Proteins (Proteins, Gene)FDA Link 01/2021
1	Sucrose (Saccharose)IBA 02/2020
1	OrexinsIBA 01/2019
1	MethoxyhydroxyphenylglycolIBA 10/2018
1	Hydroxyindoleacetic AcidIBA 10/2018
1	desmethylcitalopramIBA 01/2018
1	Escitalopram FDA Link 01/2018
1	Cytochrome P-450 CYP2C19IBA 01/2018
1	Messenger RNA (mRNA)IBA 01/2016
1	Amyloid beta-PeptidesIBA 01/2014
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2014
1	Selective Serotonin Reuptake Inhibitors (Serotonin Reuptake Inhibitors)IBA 01/2014
1	AntioxidantsIBA 01/2013
1	HDL CholesterolIBA 01/2013
1	EnzymesIBA 01/2013
1	Catechol O-Methyltransferase (Methyltransferase, Catechol)IBA 01/2013
1	superoxide dismutase 2IBA 01/2013
1	Chlorpromazine (Thorazine)FDA Link 05/2012
1	Olanzapine (Zyprexa)FDA Link 04/2010